Market News & Trends
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells From TCR-CAR+ Induced Pluripotent Stem Cells
Fate Therapeutics, Inc. recently announced the publication of preclinical study results demonstrating the successful generation, durable anti-tumor response, and functional persistence of TCR-CAR+ iPSC-derived CD8αβ…
Lexaria Bioscience Developing Powerful Tech to Treat Hypertension
Lexaria Bioscience Corp. recently announced its placement in an editorial published by NetworkNewsWir, one of 50+ trusted brands within the InvestorBrandNetwork, a multifaceted financial news…
Attralus Receives Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide)
Attralus, Inc. recently announced the US FDA has granted orphan drug designation for 124I-AT-01 (iodine (I-124) evuzamitide) as a diagnostic for the management of transthyretin…
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
Rain Therapeutics Inc. recently announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral,…
BriaCell Secures License for Promising Novel Anti-Cancer Agent
BriaCell Therapeutics Corp. recently announced it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80)…
Rigel Pharmaceuticals & Forma Therapeutics Announce Licensing Agreement for Novel Mutant IDH1 Inhibitor
Rigel Pharmaceuticals, Inc. and Forma Therapeutics, Inc. recently announced they have entered into an exclusive, worldwide license agreement to develop, manufacture, and commercialize….
US Patent Issued to HCW Biologics for Foundational Platform Technology
HCW Biologics Inc. was granted US Patent No. 11,401,324, which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric polypeptide with two target-binding domains…
Ocuphire Extends US Patent Protection for Late-Stage Drug Candidate for Reversal of Mydriasis by 5 More Years Into 2039
Ocuphire Pharma, Inc. recently announced the issuance of US Patent No. 11,400,077. The patent provides added intellectual property protection for the company’s late-stage product candidate,…
Athira Pharma Presents Data From ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Athira Pharma, Inc. recently announced Hans Moebius, MD, PhD, Athira’s Chief Medical Officer, is leading an oral presentation titled ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease…
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial
Cornerstone Pharmaceuticals, Inc. recently announced the successful completion of a Phase 1b clinical trial of CPI-613 (devimistat) in combination with gemcitabine and cisplatin for the treatment…
PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma
PolyPid Ltd. recently announced it has entered into an exclusive licensing agreement with ADVANZ PHARMA Corp. for the commercialization of its lead drug candidate, D-PLEX100 for the prevention of….
New Lipid Facility at Evonik’s Site in Hanau to Produce Clinical & Launch Quantities of Lipids for Innovative Medicines
Evonik is building a new cGMP facility to manufacture lipids for clinical development and launch of innovative medicines. The new cGMP lipid launch facility is located in….
Context Therapeutics & The Menarini Group Announce Clinical Trial Collaboration & Supply Agreement
Context Therapeutics Inc. and The Menarini Group recently announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.…
Curia Appoints Niall Condon to Lead Manufacturing
Curia recently announced the appointment of Niall Condon as President of its Manufacturing Division, with immediate effect. Condon will drive growth and be responsible for…
Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq:…
Verrica Pharmaceuticals Announces Start of Phase 3 Trial for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. recently announced Torii Pharmaceutical Co., Ltd. dosed the first patient in its Phase 3 trial of VP-102 (referred to as TO-208 in…
Avalo Therapeutics Transfers Anti-IL-18 Antibody to Apollo Therapeutics
Avalo Therapeutics, Inc. and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize….
SCHOTT Establishes Stand-Alone Company for its Pharma Business to Promote Further Growth
SCHOTT has legally established a stand-alone company for its pharma business to advance its growth strategy. As a pioneer in pharma drug containment and system solutions, the international technology….
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients With Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. recently announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary….
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates
Vaxxinity, Inc. recently presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the….
